Targeting Rare Diseases
and Critical Care
AOP Health is the European pioneer for integrated therapies for rare diseases and in critical care.
As a privately owned company AOP Health is devoted to long-term commitment, high quality, and continuity. For a small number of very special diseases the company is the sole supplier of some key therapeutic agents throughout the world.
Founding
AOP Orphan – now AOP Health – was founded in 1996 by Dr. Rudolf Widmann with the aim of developing and providing therapy options for patients with rare diseases, and then introducing the therapy options first in Austria, the European core countries of AOP Health, and finally in the international market.
Team
“AOP Health focuses on supporting the needs of the most vulnerable, often forgotten groups of patients - those with rare diseases. At AOP Health, we not only enable access to rare disease therapies, but also provide our competencies to support the entire treatment process.”
“It is our privilege to cooperate with outstanding specialists and to support them to the best of our abilities in order to help patients with rare disorders.”
Facts & Figures
AOP Health is fully dedicated to pharmaceutical and clinical development as well as commercialization of drugs for more than 20 years already.
Our motivation at AOP Health is to help patients who suffer from rare diseases. We achieve this cooperating with stakeholders of the Polish health care system. Partnerships within pharmaceutical and health care industry are crucial for finding and providing solutions for patients, especially in the treatment of orphan diseases.
Poland occupies a special position among many countries where AOP Health is represented. In this market, the company began its development in 2002 and this is where AOP Health also has one of its biggest local teams of around fifteen employees in the Marketing & Sales, and Medical for all three therapeutic divisions.
Vision & Mission
Milestones
History of more than 20 years means many significant milestones — in research, social, business spheres and regulatory affairs — that were and are important for AOP Health.
Foundation of AOP Health in Vienna
The Orphan Regulation EC no 141/2000
1st Approval of Anagrelide in Europe
European Union Expansion
Prostacyclin Analogues Approval
JAK2 Discovery
Renaissance of Interferon (IFNα)
UDCA Designation
Tetrabenazine Approval in Central Europe
Nabilone Approval in Austria
Start of the PROUD PV Study
Beta-blocker for severe sepsis
Pitolisant approval
Landiolol approval
Treprostinil and PAH
BESREMi® Approval
AOP Health headquarters team in Vienna covers all essential aspects of product development, starting with preclinical research & toxicology, extending to pharmaceutical & clinical development, including regulatory affairs, quality management & pharmacovigilance. Find out more about Science & Innovation at AOP Health in English on the global website.
Partnering is of key importance for AOP Health. It allows further developing AOP Health’s rare disease portfolio and enables to approach patients beyond company’s core markets in Europe. Find out more about cooperation ways with AOP Health using the link below.
Corporate culture
Since its very start AOP Health has borne the social responsibility of further life quality improvement for patients with severe, rare and life-threatening diseases. We at AOP Health conduct intensive research for this purpose, believing that developing and providing solutions for patients is the most important part of the AOP Health corporate responsibility. When it comes to wanting the best for the patients, we stand side-by-side with each other as a team, with researches, physicians, therapists, caregivers, patient organizations and other stakeholders.
AOP Health is keen to keep one of its greatest assets – it is closely networked with the key specialists in all markets and is therefore able to help patients with rare diseases from Austria throughout the world.
From its inception AOP Health's culture is shaped by the entrepreneurial spirit of its founder. We are proud to be a company that encourages employees to come up with new ideas and to show ownership and initiative every day. To help neglected patients with rare diseases is our key motivator. Through close interaction with the scientific community, care givers and partners we aim to provide therapies and help patients beyond just providing drugs.
The future
Thanks to our advancements in the field of therapies, an increasing number of patients survive their disease or are able to live with it for a longer period of time. In the next few decades, personalized medicine, individual treatment opportunities will emerge more and more as the standard in AOP Health’s therapy concepts as well.
Novel technologies such as next-generation sequencing (NGS) will play an equally crucial role as the increasing quantities of big data and conclusions derived from the daily lives of patients also beyond the strictly regulated conditions of clinical trials, e.g. real-world evidence.
Furthermore, the increasing health competence, health literacy of patients and their family members will also determine the future of pharma and health care sector.